Challenges and Potential Solutions to Advance Global Cancer Drug Development

Area of Science:

• Oncology
• Clinical Research
• Health Technology Assessment

Background:

• Innovative cancer therapies face challenges in patient access despite advancements.
• Current approaches often lack sufficient patient-centricity and meaningful patient input.

Purpose of the Study:

• To highlight the need for patient-centric approaches in oncology drug development.
• To identify strategies for improving data robustness and accelerating patient access to novel cancer treatments.

Main Methods:

• Review of current challenges in oncology drug development and patient access.
• Analysis of multi-stakeholder consensus on patient involvement and data generation.
• Exploration of potential solutions including study design and endpoint validation.

Main Results:

• Inadequate patient access to innovative cancer therapies persists.
• Meaningful patient input from trial design to health technology assessment is essential.
• Improved data robustness and novel surrogate endpoints can expedite access.

Conclusions:

• Patient-centricity and robust data are key to improving access to novel cancer drugs.
• Smarter clinical trial designs and validated surrogate endpoints are needed.
• Timely, evidence-based decisions are critical for enhancing the patient experience.